This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Celtic Pharmaceutical Holdings L.P.
Drug Names(s): XR309
Description: XR309 and XR310 are fully human monoclonal antibodies that bind to different sites on a proprietary antigen, CTA1 that is present on a wide variety of tumours but has limited presence on normal tissue. The antibodies are being developed as radioimmunotherapies for the treatment of solid tumours.
Deal Structure: In September 2005, Celtic Pharmaceutical completed its takeover of Xenova Group plc and took full ownership of its drug candidate portfolio.
Additional information available to subscribers only: